New Triple-Drug attack on blood cancer shows promise
NCT ID NCT03580928
Summary
This study is testing whether a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—is a safe and effective first treatment for chronic lymphocytic leukemia (CLL). The trial involves 72 adults with CLL who have not had prior treatment but need it based on their symptoms. Researchers aim to see if this combination can deeply reduce or eliminate cancer cells, potentially allowing some patients to stop treatment and restart only if the cancer returns.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Stamford Hospital/Bennett Cancer Center
Stamford, Connecticut, 06904, United States
Conditions
Explore the condition pages connected to this study.